TSAAI 2025 Annual Meeting

Pigeon Forge, TN US
July 18, 2025 to July 20, 2025

The Tennessee Society of Allergy, Asthma and Immunology (TSAAI) was established to coordinate the efforts of specialists in allergy, asthma and immunology in the state of Tennessee, principally for scientific and education purposes and to promote the highest standards of practitioners in the fields of allergy, asthma and immunology.

TSAAI's annual educational meeting consists of presentations by recognized speakers in the field of allergy, asthma and immunology.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunology and the Tenessee Society of Allergy, Asthma & Immunology (TSAAI). The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

No commercial support was received for this activity.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

At the conclusion of this Activity learners should be able to…
1.    Diagnose conditions of upper airway problems associated with asthma or conditions with symptoms similar to asthma.
2.    Assess asthma co-morbidities and modify treatment goals for asthma.
3.    Attendees will learn how to utilize A/I and gain the skills necessary to better manage the medical challenges they face in clinic and learn how to more efficiently run a medical practice using A/I.
4.    Recognize laryngeal disorders contributing to asthma symptoms
5.    Identify how to diagnose hyper-IgE disorders, conditions related to eosinophilia, allergy and anaphylaxis.
6.    Discuss novel treatment strategies for HAE and anaphylaxis.
7.    Identify patients with secondary hypogammaglobulinemia that will benefit from immunoglobulin replacement.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Attendance
Course opens: 
07/18/2025
Course expires: 
12/31/2025
Event starts: 
07/18/2025 - 4:00pm CDT
Event ends: 
07/20/2025 - 12:35pm CDT
Rating: 
0

TSAAI 2025 Annual Meeting
Dollywood’s HeartSong Conference Center, Pigeon Forge, TN
July 18-20, 2025

Friday, July 18, 2025

4:00 – 5:00 pm     Attendee Early Check-In (Optional) - Conference Center Hallway

Saturday, July 19, 2025 
All CME Sessions will be held in Salon C/D

7:15 – 7:45 am     Attendee Check-In

7:15 – 7:45 am     Breakfast & exhibits (Salon A/B)

7:45 – 8:00 am     Introduction, Ty Prince, MD

8:00 – 9:00 am     AI in Allergy, Chris Chang, MD
Q & A

9:00 – 10:00 am     Hereditary Angioedema, Marc Riedl, MD
Q & A

10:00 – 10:30 am     Break & exhibits (Salon A/B)

10:30 – 11:30 am     The Sights and Sounds of Asthma, Nina Ramirez, MD
Q & A

11:30 – 12:30 pm     Alternate Paths to Immunodeficiency: Secondary and Beyond, Yasmin Khan, MD
Q & A

Sunday, July 20, 2025
All CME Sessions will be held in Salon C/D

7:15 – 7:45 am     Breakfast & exhibits (Salon A/B)
    
8:00 – 9:00 am     GERD, Laryngeal Disorders and Vocal Cord Dysfunction, Dennis Ledford, MD
Q & A
    
9:00 – 10:00 am     Anaphylaxis, Jay Lieberman, MD
Q & A

10:00 – 10:30 am     Break & exhibits (Salon A/B)

10:30 – 11:30 am     Bronchiectasis, Allergic Bronchopulmonary Aspergillosis, Cystic Fibrosis, Sleep Apnea and Others, Dennis Ledford, MD
Q & A

11:30 – 12:30 pm     Hyper IgE, Hypereosinophilia - When to Worry About More Than Allergy, Kelli Williams, MD
Q & A        

12:30 pm     Meeting adjourn

Dollywood HeartSong Conference Center
1210 Dollywood Resorts Blvd
Pigeon Forge, TN 37863
United States

All relevant financial relationships with ineligible companies have been mitigated.
  
Christopher Chang, MD, Speaker
    Speaker: ADMA
    
Nicholas Kolinsky, DO, Program Chair and Planner
    Advisor: AstraZeneca, Pharming, Hikma, ADMA Biologics, KalVista, Blueprint Medicines
    Speaker: AstraZeneca, Amgen, Hikma, GlaxoSmithKline, CSL Behring, Sanofi, Regeneron, Grifols
 
Dennis Ledford, MD, Speaker
    Consultant: Amgen
 
Jay Lieberman, MD, Speaker
    Advisor: ARS, Aquestive, Theravia, Genentech, Kaleo
    Consultant: ARS, Theravia, Amgen, Abbvie, Celldex, Genentech, Kaleo
    Researcher: DBV

 Tidence Prince, MD, Program Chair and Planner
    Speaker: AstraZeneca, GSK, Takeda
 
Nina Ramirez, MD, Speaker
    Advisor: AstraZeneca, Sanofi Regeneron, Amgen
    Speaker: AstraZeneca, Sanofi Regeneron
 
Marc Riedl, MD MS, Speaker
    Consultant: Astria, Biocryst, Biomarin, Celldex, CSL Behring, Cycle Pharmacy, Grifols, Intellia, Ionis, Kalvista, Novartis, Pharming, Pharvaris, Sanofi-Regeneron, Takeda
    Researcher: Astria, Biocryst, Biomarin, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda
    Speaker: Biocryst, CSL Behring, Grifols, Pharming, Takeda 
 
Kelli Williams, MD, Speaker
    Advisor: Pharming Healthcare, Amgen Inc.
    Consultant: ADMA Biologics, Pharming Healthcare, Amgen Inc.
    Researcher: AstraZeneca, GSK, Cogent Biosciences, ADMA Biologics, Amgen Inc.
    Speaker: Pharming Healthcare 

The following have no relevant financial relationships with ineligible companies to disclose:

Yasmin Khan, MD, Speaker
Karthik Krishnan, MD, Program Chair and Planner
Michelle Kittle, Meeting Coordinator
Chloe Miller, Meeting Coordinator

Available Credit

  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Attendance
Please login or create an account to take this course.